Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Precision BioSciences ( (DTIL) ) has issued an announcement.
On January 12, 2026, Precision BioSciences outlined its 2026 strategic priorities centered on advancing its two lead ARCUS-based in vivo gene editing programs—PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy—while emphasizing a solid cash position of approximately $137 million as of December 31, 2025, which it expects will support key data milestones through 2028. The company reported encouraging safety and antiviral activity data from multiple dosing cohorts in its global Phase 1/2a ELIMINATE-B trial for PBGENE-HBV, with plans to complete dosing in Cohorts 3, 4, and 5, select an optimal regimen to enable stopping nucleos(t)ide analog treatment, and move into trial expansion, while also preparing to initiate patient dosing in the Phase 1/2 FUNCTION-DMD trial in early 2026 and deliver initial Duchenne data by year-end; additional value drivers include partnered programs ECUR-506 and azer-cel, which have reached significant regulatory and clinical milestones and triggered an $8 million payment in late 2025, underscoring Precision’s strengthened financial and strategic position in the gene editing field.
The most recent analyst rating on (DTIL) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
The overall stock score is primarily impacted by the company’s poor financial performance, characterized by declining revenues and substantial losses. Technical analysis also indicates a bearish trend, with the stock trading below key moving averages. Valuation metrics further highlight the company’s challenges, with a negative P/E ratio and no dividend yield. The promising trial results are a positive development but do not significantly offset the financial and technical concerns.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences, Inc., based in Durham, N.C., is a clinical-stage gene editing company that uses its proprietary ARCUS genome editing platform to develop in vivo gene editing therapies aimed at providing lasting cures for genetic and infectious diseases with high unmet medical need, including chronic hepatitis B and Duchenne muscular dystrophy.
Average Trading Volume: 239,728
Technical Sentiment Signal: Sell
Current Market Cap: $94.36M
Find detailed analytics on DTIL stock on TipRanks’ Stock Analysis page.